Search the GHTC website

Global health R&D delivers for Montana

US government investment in global health R&D has delivered

Amount
$43.8 million
to Montana research institutions
Jobs
550+ new jobs
for Montana
Montana's top USG-funded global health R&D institutions

Montana's top USG-funded global health R&D institutions

University of Montana (including Montana Biotechnology Center)
$35.9 million
Inimmune
$4.3 million
Montana State University in Bozeman
$2 million
GlyderTech
$1.2 million
Montana Molecular, LLC
$300 thousand

Montana's top areas of global health R&D by USG funding

5.8%
Arenaviral hemorrhagic fevers (including Lassa fever)
16.7%
COVID-19
3.7%
Mpox
30.1%
Tuberculosis
41%
Multi-disease/health area R&D
2.7%
Other
Bunyaviral diseases (including CCHF, RVF, SFTS)
Dengue
Reproductive health
Rheumatic fever
Salmonella infections
Global health R&D at work in Montana

A research team at Montana State University has discovered that the gene activity of the malaria parasite is governed by its own internal clock and does not rely on cues from its human host. It is a finding that could unlock new ways to fight this deadly disease that sickens nearly 250 million people and kills over a half million globally each year. When a person is infected with malaria, the parasites in their body attack, multiply, and burst in a rhythmic, regularized pattern, causing the disease’s telltale cycle of fevers and chills. Since this pattern is controlled by genes within the parasite that act as a timekeeping mechanism, the long-term goal of the research is to find ways to disrupt or disable these “clock genes,” helping the immune system better fight off its parasitic invaders.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PMI